Proactive Investors - Run By Investors For Investors

'We have absolutely no side effect profile in Lupuzor at all' says ImmuPharma chairman

Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM) spoke to Proactive to give an update on the company's progress with its phase-III clinical trial of Lupuzor, a treatment for Lupus - a life threatening auto-immune disease.

''We've already had two patients complete 12 months of the study, over 80% of patients have already completed 3 months of their treatment and most importantly we've seen no adverse events in the study to date - and that in terms of the profile of the drug is very important''.

''In all the studies we've seen to date, we have absolutely no side effect profile with this drug at all'', says McCarthy. ''That product profile at the moment, is standing up and that's what we're seeing''.

Meet Horizonte Minerals Plc, Tethyan Resources PLC, Green Dragon Gas Ltd. and Zenyatta Ventures at our event, London, 31 May 2017. Register here »
Why Invest In ImmuPharma PLC? Read More Here

Register here to be notified of future ImmuPharma PLC articles
View full IMM profile View Profile

ImmuPharma PLC Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use